Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Options Strategies & the Zacks Rank
- PFP 5/21: Below the Surface
- AWS 5/20: The Fed In Focus This Week
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/20/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
| EAGLE BULK S | EGLE | 7.84% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
AstraZeneca PLC’s ( AZN - Analyst Report ) global biologics division, MedImmune, is set to streamline its infectious disease and vaccines research, development and operations. As part of the restructuring, AstraZeneca is closing its California sites at Mountain View and Santa Clara. However, the company will keep its site at Hayward operational.
As a result of the restructuring, AstraZeneca expects that 300 positions will be impacted of which 100 will be shifted to the company’s other sites including Hayward. This operation is expected to be over in 2014.
AstraZeneca believes that the changes will help in innovation across its therapeutics areas and also aid product development. This will also result in reduction of fixed cost associated with the sites. The company reaffirmed its commitment to infectious diseases and vaccines research and development, mentioning that the changes will not affect the supply of vaccines.
Our Take
AstraZeneca is on the back foot due to generic competition faced by its many of its drugs. Arimidex, Toprol-XL, Seroquel IR and Merrem are already facing generic competition in the US. Additionally, Nexium generics are expected in the US in 2014. Generic competition was primarily responsible for the $2 billion loss of revenues in 2011.
Moreover, AstraZeneca’s drugs operate in a highly competitive environment. AstraZeneca’s lead drug, Crestor, primarily competes with Pfizer Inc.’s ( PFE - Analyst Report ) Lipitor and Merck & Co. Inc.’s ( MRK - Analyst Report ) Zocor/Vytorin. Nexium competes with Pfizer’s Protonix. The company is looking to drive the bottom-line through cost-cutting initiatives and share buybacks.
We currently have a Neutral recommendation on AstraZeneca. The stock carries a Zacks #3 Rank (Hold rating) in the short term.
Read the full Analyst Report on AZN
Read the full Analyst Report on PFE
Read the full Analyst Report on MRK